Please try another search
For the fiscal year ended 31 December 2021, Bio Synectics Inc revenues increased from W229.2M to W569.6M. Net loss decreased 42% to W1.07B. Revenues reflect Finished Goods Revenues increase from W213M to W498.1M, Services Revenue increase from W16.2M to W71.5M. Lower net loss reflects Salaries & Wages decrease of 14% to W308.6M (expense), Depreciation in R&D decrease of 9% to W94.5M (expense).
Period Ending: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Revenue | 569.58 | 229.19 | 378.6 | 225.22 |
Gross Profit | 212.91 | 54.61 | 99.26 | 72.17 |
Operating Income | -1075.27 | -1722.78 | -1144.82 | -1089.36 |
Net Income | -1070.93 | -1838.23 | -1115.09 | -1045.59 |
Period Ending: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Assets | 1706.35 | 3556.69 | 4443.45 | |
Total Liabilities | 580.5 | 602.87 | 469.07 | |
Total Equity | 1125.85 | 2953.82 | 3974.38 |
Period Ending: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Period Length: | 0 Months | 12 Months | 12 Months | 12 Months |
Cash From Operating Activities | -967.6 | -1033.43 | -888.04 | |
Cash From Investing Activities | 962.12 | 843.36 | -2453.81 | |
Cash From Financing Activities | 0 | 106.72 | 84.67 | |
Net Change in Cash | -5.48 | -83.35 | -3257.18 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review